Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 204

1.

Metformin in cancer therapy: a new perspective for an old antidiabetic drug?

Ben Sahra I, Le Marchand-Brustel Y, Tanti JF, Bost F.

Mol Cancer Ther. 2010 May;9(5):1092-9. doi: 10.1158/1535-7163.MCT-09-1186. Epub 2010 May 4. Review.

2.

The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level.

Ben Sahra I, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P, Tanti JF, Le Marchand-Brustel Y, Bost F.

Oncogene. 2008 Jun 5;27(25):3576-86. doi: 10.1038/sj.onc.1211024. Epub 2008 Jan 21.

PMID:
18212742
3.

Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by activating AMP-activated protein kinase.

Hosono K, Endo H, Takahashi H, Sugiyama M, Uchiyama T, Suzuki K, Nozaki Y, Yoneda K, Fujita K, Yoneda M, Inamori M, Tomatsu A, Chihara T, Shimpo K, Nakagama H, Nakajima A.

Mol Carcinog. 2010 Jul;49(7):662-71. doi: 10.1002/mc.20637.

PMID:
20564343
4.

Metformin: its emerging role in oncology.

Micic D, Cvijovic G, Trajkovic V, Duntas LH, Polovina S.

Hormones (Athens). 2011 Jan-Mar;10(1):5-15. Review.

5.

Metformin and cancer therapy.

Bost F, Sahra IB, Le Marchand-Brustel Y, Tanti JF.

Curr Opin Oncol. 2012 Jan;24(1):103-8. doi: 10.1097/CCO.0b013e32834d8155. Review.

PMID:
22123231
6.

Metformin amplifies chemotherapy-induced AMPK activation and antitumoral growth.

Rocha GZ, Dias MM, Ropelle ER, Osório-Costa F, Rossato FA, Vercesi AE, Saad MJ, Carvalheira JB.

Clin Cancer Res. 2011 Jun 15;17(12):3993-4005. doi: 10.1158/1078-0432.CCR-10-2243. Epub 2011 May 4.

7.

Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells.

Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M.

Cancer Res. 2006 Nov 1;66(21):10269-73. Epub 2006 Oct 23.

8.

AMP-activated protein kinase in metabolic control and insulin signaling.

Towler MC, Hardie DG.

Circ Res. 2007 Feb 16;100(3):328-41. Review.

9.

Obesity, hyperinsulinemia and breast cancer: novel targets and a novel role for metformin.

Wysocki PJ, Wierusz-Wysocka B.

Expert Rev Mol Diagn. 2010 May;10(4):509-19. doi: 10.1586/erm.10.22. Review.

PMID:
20465505
10.

Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth.

Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, Zhao F, Viollet B, Thompson CB.

Cancer Res. 2007 Jul 15;67(14):6745-52.

11.
12.

Dual antiglioma action of metformin: cell cycle arrest and mitochondria-dependent apoptosis.

Isakovic A, Harhaji L, Stevanovic D, Markovic Z, Sumarac-Dumanovic M, Starcevic V, Micic D, Trajkovic V.

Cell Mol Life Sci. 2007 May;64(10):1290-302.

PMID:
17447005
13.

Molecular targets of metformin antitumor action.

Sośnicki S, Kapral M, Węglarz L.

Pharmacol Rep. 2016 Oct;68(5):918-25. doi: 10.1016/j.pharep.2016.04.021. Epub 2016 May 9. Review.

PMID:
27362768
15.

Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase.

Algire C, Amrein L, Zakikhani M, Panasci L, Pollak M.

Endocr Relat Cancer. 2010 Jun 1;17(2):351-60. doi: 10.1677/ERC-09-0252. Print 2010 Jun.

16.

The antidiabetic drug metformin inhibits uterine leiomyoma cell proliferation via an AMP-activated protein kinase signaling pathway.

Li B, Takeda T, Tsuiji K, Kondo A, Kitamura M, Wong TF, Yaegashi N.

Gynecol Endocrinol. 2013 Jan;29(1):87-90. doi: 10.3109/09513590.2012.706668. Epub 2012 Jul 26.

PMID:
22835064
17.

New perspective for an old antidiabetic drug: metformin as anticancer agent.

Leone A, Di Gennaro E, Bruzzese F, Avallone A, Budillon A.

Cancer Treat Res. 2014;159:355-76. doi: 10.1007/978-3-642-38007-5_21. Review.

PMID:
24114491
18.

Metformin and cancer: licence to heal?

Papanas N, Maltezos E, Mikhailidis DP.

Expert Opin Investig Drugs. 2010 Aug;19(8):913-7. doi: 10.1517/13543784.2010.499122.

PMID:
20557275
19.

Metformin action on AMP-activated protein kinase: a translational research approach to understanding a potential new therapeutic target.

Boyle JG, Salt IP, McKay GA.

Diabet Med. 2010 Oct;27(10):1097-106. doi: 10.1111/j.1464-5491.2010.03098.x. Review.

PMID:
20854376
20.

Effects of metformin on endometrial cancer cell growth in vivo: a preoperative prospective trial.

Mitsuhashi A, Kiyokawa T, Sato Y, Shozu M.

Cancer. 2014 Oct 1;120(19):2986-95. doi: 10.1002/cncr.28853. Epub 2014 Jun 10.

Supplemental Content

Support Center